📣 VC round data is live. Check it out!
- Public Comps
- GRAIL
GRAIL Valuation Multiples
Discover revenue and EBITDA valuation multiples for GRAIL and similar public comparables like Dr. Lal PathLabs, HeartFlow, Insight Lifetech, Telix Pharmaceuticals and more.
GRAIL Overview
About GRAIL
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Founded
2015
HQ

Employees
1.0K
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialGRAIL Financials
GRAIL reported last 12-month revenue of $161M and negative EBITDA of ($352M).
In the same LTM period, GRAIL generated ($15M) in gross profit, ($352M) in EBITDA losses, and had net loss of ($417M).
Revenue (LTM)
GRAIL P&L
In the most recent fiscal year, GRAIL reported revenue of $147M and EBITDA of ($378M).
GRAIL is unprofitable as of last fiscal year, with gross margin of (43%), EBITDA margin of (257%), and net margin of (277%).
Financial data powered by Morningstar, Inc.
GRAIL Stock Performance
GRAIL has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
GRAIL's stock price is $64.40.
GRAIL share price decreased by 10.2% in the last 30 days, and increased by 25.2% in the last year.
GRAIL has an EPS (earnings per share) of $-9.51.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | -10.2% | -10.2% | 24.6% | 25.2% | $-9.51 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGRAIL Valuation Multiples
GRAIL trades at 12.4x EV/Revenue multiple, and (5.7x) EV/EBITDA.
EV / Revenue (LTM)
GRAIL Financial Valuation Multiples
As of June 2, 2026, GRAIL has market cap of $3B and EV of $2B.
GRAIL has a P/E ratio of (6.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GRAIL Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


GRAIL Margins & Growth Rates
GRAIL grew revenue by 22% but EBITDA decreased by 20% in the last fiscal year.
In the most recent fiscal year, GRAIL reported gross margin of (43%), EBITDA margin of (257%), and net margin of (277%).
GRAIL Margins
GRAIL Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
GRAIL Operational KPIs
GRAIL's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.5M for the same period.
GRAIL's Rule of 40 is (146%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GRAIL's Rule of X is (113%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
GRAIL Competitors
GRAIL competitors include Dr. Lal PathLabs, HeartFlow, Insight Lifetech, Telix Pharmaceuticals, BGI Genomics, Genus, 10x Genomics, Veracyte, Diasorin and Fleury.
Most GRAIL public comparables operate across Medical Imaging & Diagnostics, Diagnostics & Genomics, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 10.2x | 8.9x | 31.9x | 31.4x | |||
| 14.4x | 12.8x | (76.6x) | (65.9x) | |||
| 29.3x | - | 131.9x | - | |||
| 4.3x | 4.0x | 80.4x | 69.4x | |||
| 3.4x | 3.3x | 42.7x | 39.0x | |||
| 2.6x | 2.6x | 14.5x | 13.2x | |||
| 5.1x | 5.2x | 843.7x | (71.8x) | |||
| 6.7x | 6.3x | 24.2x | 23.3x | |||
This data is available for Pro users. Sign up to see all GRAIL competitors and their valuation data. Start Free Trial | ||||||
GRAIL VC Funding History
Before going public, GRAIL raised $2B in total equity funding, across 4 rounds.
Last private valuation of GRAIL was $6B, after raising $390M in May 2020 from CPP Investments, Huangpu River Capital, Illumina, and 1 other investor.
GRAIL Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GRAIL
| When was GRAIL founded? | GRAIL was founded in 2015. |
| Where is GRAIL headquartered? | GRAIL is headquartered in United States. |
| How many employees does GRAIL have? | As of today, GRAIL has over 1K employees. |
| Who is the CEO of GRAIL? | GRAIL's CEO is Robert Ragusa. |
| Is GRAIL publicly listed? | Yes, GRAIL is a public company listed on Nasdaq. |
| What is the stock symbol of GRAIL? | GRAIL trades under GRAL ticker. |
| When did GRAIL go public? | GRAIL went public in 2024. |
| Who are competitors of GRAIL? | GRAIL main competitors include Dr. Lal PathLabs, HeartFlow, Insight Lifetech, Telix Pharmaceuticals, BGI Genomics, Genus, 10x Genomics, Veracyte, Diasorin, Fleury. |
| What is the current market cap of GRAIL? | GRAIL's current market cap is $3B. |
| What is the current revenue of GRAIL? | GRAIL's last 12 months revenue is $161M. |
| What is the current revenue growth of GRAIL? | GRAIL revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of GRAIL? | Current revenue multiple of GRAIL is 12.4x. |
| Is GRAIL profitable? | No, GRAIL is not profitable. |
| What is the current EBITDA of GRAIL? | GRAIL has negative EBITDA and is not profitable. |
| What is GRAIL's EBITDA margin? | GRAIL's last 12 months EBITDA margin is (219%). |
| What is the current EV/EBITDA multiple of GRAIL? | Current EBITDA multiple of GRAIL is (5.7x). |
| What is the current FCF of GRAIL? | GRAIL's last 12 months FCF is ($295M). |
| What is GRAIL's FCF margin? | GRAIL's last 12 months FCF margin is (183%). |
| What is the current EV/FCF multiple of GRAIL? | Current FCF multiple of GRAIL is (6.8x). |
| How many companies GRAIL has acquired to date? | GRAIL hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies GRAIL has invested to date? | GRAIL hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to GRAIL
Lists including GRAIL
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.